# First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

> **NCT03309241** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 25 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** PF-06882961
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03309241
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-17
- **Primary completion:** 2018-02-21
- **Final completion:** 2018-03-22
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03309241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03309241, "First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03309241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*